The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Above-label doses of octreotide-LAR in patients with metastatic small-intestinal carcinoid tumors.
Jill M. Weber
No relevant relationships to disclose
Max Feldman
No relevant relationships to disclose
Larry Kvols
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Jonathan R. Strosberg
Consultant or Advisory Role - Novartis
Research Funding - Novartis